ArticleTransboundary and emerging diseases2025
Distinctive Immunological Signatures Define Foot-and-Mouth Disease Virus Persistence in Vaccinated Cattle.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Foot-and-Mouth Disease Virus Persistence Divergence Within Serotypes and Vaccine Doses in Vaccinated Cattle.Transboundary and emerging diseases · 2026Article
- Distinctive Immunological Signatures Define Foot-and-Mouth Disease Virus Persistence in Vaccinated Cattle.Transboundary and emerging diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with foot-and-mouth disease virus (FMDV) develops in over 50% of infected ruminants, presenting major obstacles to disease control and eradication. To clarify host immune correlates of FMDV persistence, we characterized systemic T- and B-cell responses, as well as mucosal responses in 15 vaccinated cattle following experimental FMDV challenge. The prevalence of FMDV persistence was 53.3%. While peripheral CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.